Epcoritamab

Bispecific CD20-directed CD3 T Cell Engager — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Key facts

Epcoritamab is a drug in the Bispecific CD20-directed CD3 T Cell Engager class catalogued in DrugCentral. It was first approved by the FDA in 2023. Its mechanism of action is classified as CD20-directed Antibody Interactions, CD3 Receptor Agonists and CD3-directed Antibody Interactions. DrugCentral lists 2 molecular targets, including CD3E|CD3G|CD3D and MS4A1. Recorded indications include Relapsed or refractory diffuse large B-cell lymphoma.

• Drug class: Bispecific CD20-directed CD3 T Cell Engager.
• Mechanism of action: CD20-directed Antibody Interactions; CD3 Receptor Agonists; CD3-directed Antibody Interactions.
• Molecular targets: CD3E|CD3G|CD3D and MS4A1 (2 listed in DrugCentral).
• Indications: Relapsed or refractory diffuse large B-cell lymphoma.
• ATC code: L01FX27 (Other monoclonal antibodies and antibody drug conjugates).

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Relapsed or refractory diffuse large B-cell lymphoma

Mechanism & targets

• Mechanism of action (MoA): CD20-directed Antibody Interactions; CD3 Receptor Agonists; CD3-directed Antibody Interactions; Cytochrome P450 Inhibitors
• Established pharmacologic class: Bispecific CD20-directed CD3 T Cell Engager

Molecular targets (2)

Target	Gene	Action	Activity
T-cell surface glycoprotein CD3	CD3E|CD3G|CD3D	other	EC50 8.80
B-lymphocyte antigen CD20	MS4A1	other	EC50 8.61

Regulatory approvals (2)

Date	Agency	Marketed as	Applicant	Orphan
2023-09-22	EMA	—	AbbVie Deutschland GmbH & Co. KG
2023-05-19	FDA	—	GENMAB US, INC.

ATC classification

ATC code	Therapeutic hierarchy
L01FX27	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES › Other monoclonal antibodies and antibody drug conjugates

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Cytokine release syndrome	4532.2
Immune effector cell-associated neurotoxicity syndrome	790.8
Febrile neutropenia	378.0
Pyrexia	319.4
COVID-19	250.5
Cytomegalovirus infection reactivation	171.4
Sepsis	135.6
COVID-19 pneumonia	129.0
Hypogammaglobulinaemia	121.6
Tumour pseudoprogression	116.2
Cytomegalovirus infection	114.7
Diffuse large B-cell lymphoma	114.0

Chemical structure

• Molecular formula: —
• Molecular weight: —
• CAS number: —
• InChIKey: —
• PubChem CID: —

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Epcoritamab used for?

DrugCentral lists the following indications for Epcoritamab: Relapsed or refractory diffuse large B-cell lymphoma.

How does Epcoritamab work?

Epcoritamab is classified as CD20-directed Antibody Interactions, CD3 Receptor Agonists and CD3-directed Antibody Interactions; its molecular targets in DrugCentral include CD3E|CD3G|CD3D and MS4A1.

When was Epcoritamab first approved?

Epcoritamab was first approved by the FDA in 2023.

What drug class does Epcoritamab belong to?

Epcoritamab is in the Bispecific CD20-directed CD3 T Cell Engager class.

Sources

• DrugCentral drug card 5734 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL4650393 — compound record and bioactivity
• DrugBank DB16672 — drug record
• FDA UNII D6OMY2L0WA — substance identity
• DailyMed: FDA labels for Epcoritamab — current prescribing information (label search)
• UniProt P11836 (MS4A1) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.